keyword
MENU ▼
Read by QxMD icon Read
search

Pre-market approval

keyword
https://www.readbyqxmd.com/read/27881103/demonstration-of-early-efficacy-results-of-the-delayed-release-combination-of-doxylamine-pyridoxine-for-the-treatment-of-nausea-and-vomiting-of-pregnancy
#1
Gideon Koren, Shannon Clark, Gary D V Hankins, Steve N Caritis, Jason G Umans, Menachem Miodovnik, Donald R Mattison, Ilan Matok
BACKGROUND: Nausea and vomiting of pregnancy (NVP) affects up to 80% of expecting mothers. In April 2013 the FDA approved the delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (Diclegis®) for NVP, based in part, on the results of a phase III randomized trial demonstrating the efficacy of this drug combination [study drug marketed under the trade name Diclectin® in Canada and Diclegis® in the United States] compared to placebo in pregnant women. Study drug dosing occurred for 14 days, which is substantially longer than what has been performed in similar studies...
November 24, 2016: BMC Pregnancy and Childbirth
https://www.readbyqxmd.com/read/27875916/new-era-in-treatment-options-of-chronic-hepatitis-c-focus-on-safety-of-new-direct-acting-antivirals-daas
#2
Cristina Scavone, Liberata Sportiello, Concetta Rafaniello, Annamaria Mascolo, Maurizio Sessa, Francesco Rossi, Annalisa Capuano
New direct-acting antivirals have changed hepatitis C virus infection management extremely. Areas covered: The pharmacological management of HCV infection and the main characteristics of new DAA therapies have been discussed. In order to analyse safety data regarding DAA therapies, a narrative review was performed searching for safety results of main second generation DAAs pivotal and post-marketing studies. Data on main DAAs drug-drug interactions have also been discussed. Results of main DAAs pivotal studies revealed that these drugs were frequently associated to adverse events such as asthenia, headache, nausea, and insomnia...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27819246/21st-century-pharmacovigilance-efforts-roles-and-responsibilities
#3
REVIEW
Peter J Pitts, Hervé Le Louet, Yola Moride, Rena M Conti
In an era when the number of expedited and conditional review pathways for newly available brand-name drugs and biosimilar medicines to treat serious and life-threatening diseases is increasing, defining pharmacovigilance has never been more crucial. 21st century pharmacovigilance is not merely about uncovering, reporting, and addressing adverse events associated with already approved and marketed agents, but can be described as the systematic monitoring of the process of pre-market review and post-market surveillance, which includes the use of medicines in everyday practice...
November 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27777897/chronic-cholestatic-liver-injury-attributable-to-vedolizumab
#4
Jonathan G Stine, Jennifer Wang, Brian W Behm
Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic cholestatic liver injury.
September 28, 2016: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/27754016/br-04-2-concentration-response-modeling-of-antihypertensive-drugs-implication-in-clinical-development
#5
Dong-Seok Yim
In the early phase of clinical development of antihypertensive drugs, quantitative modeling to predict their dose-concentration-response relationship is important to plan future clinical development and finding optimal dosage regimen at marketing approval. Two cases of concentration-response models of antihypertensive are presented here.Case 1: Carvedilol is a α1- and nonselective β- adrenergic receptor antagonist currently used for the management of mild-to-moderate essential hypertension and congestive heart failure...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27723249/microbial-alkane-production-for-jet-fuel-industry-motivation-state-of-the-art-and-perspectives
#6
Lorena Jiménez-Díaz, Antonio Caballero, Natalia Pérez-Hernández, Ana Segura
Bio-jet fuel has attracted a lot of interest in recent years and has become a focus for aircraft and engine manufacturers, oil companies, governments and researchers. Given the global concern about environmental issues and the instability of oil market, bio-jet fuel has been identified as a promising way to reduce the greenhouse gas emissions from the aviation industry, while also promoting energy security. Although a number of bio-jet fuel sources have been approved for manufacture, their commercialization and entry into the market is still a far way away...
October 10, 2016: Microbial Biotechnology
https://www.readbyqxmd.com/read/27642927/br-04-2-concentration-response-modeling-of-antihypertensive-drugs-implication-in-clinical-development
#7
Dong-Seok Yim
In the early phase of clinical development of antihypertensive drugs, quantitative modeling to predict their dose-concentration-response relationship is important to plan future clinical development and finding optimal dosage regimen at marketing approval. Two cases of concentration-response models of antihypertensive are presented here.Case 1: Carvedilol is a α1- and nonselective β- adrenergic receptor antagonist currently used for the management of mild-to-moderate essential hypertension and congestive heart failure...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27610084/current-status-of-the-new-antiepileptic-drugs-in-chronic-pain
#8
REVIEW
Harpreet S Sidhu, Akshay Sadhotra
Antiepileptic drugs (AEDs) are extensively used worldwide to treat a wide range of disorders other than epilepsy, such as neuropathic pain, migraine, and bipolar disorder. Due to this situation more than 20 new third-generation AEDs have been introduced in the market recently. The future design of new AEDs must also have potential to help in the non-epileptic disorders. The wide acceptance of second generation AEDs for the management of various non-epileptic disorders has caused the emergence of generics in the market...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27609249/overview-of-the-2016-u-s-food-and-drug-administration-circulatory-system-devices-advisory-panel-meeting-on-the-absorb-bioresorbable-vascular-scaffold-system
#9
Arie Steinvil, Toby Rogers, Rebecca Torguson, Ron Waksman
OBJECTIVES: This study aims to describe the discussions and recommendations made during the U.S. Food and Drug Administration (FDA) Circulatory System Device Panel pre-market approval application for the Absorb Bioresorbable Vascular Scaffold (BVS) System. BACKGROUND: The Absorb BVS System is a first-of-its-kind fully bioresorbable percutaneous coronary intervention technology. The absorb BVS was studied in the ABSORB III (A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions) trial, the pivotal U...
September 12, 2016: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/27554637/no-meaningful-association-between-suicidal-behavior-and-the-use-of-il-17a-neutralizing-or-il-17ra-blocking-agents
#10
Andrea Chiricozzi, Marco Romanelli, Rosita Saraceno, Tiago Torres
INTRODUCTION: An emerging class of agents blocking IL-17 signaling represents a very promising therapeutic approach. One of these agents, brodalumab, has been associated with an increased risk of suicide behavior. AREAS COVERED: This review sought to provide an overview strictly focused on suicide behavior signals related to the use of IL-17 agents. Data collection regarding this peculiar safety aspect was primarily based on: (i) a revision of safety outcomes belonging to phase II and phase III trials; (ii) a systematic search using the Pubmed Medline database; and (iii) collecting recent data issued as posters or communications in eminent international meetings...
August 31, 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27551882/peginesatide-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-an-unfulfilled-promise
#11
Terhi Hermanson, Charles L Bennett, Iain C Macdougall
INTRODUCTION: The introduction of recombinant human erythropoietin revolutionized the management of anemia in patients with chronic kidney disease (CKD). In order to circumvent costly recombinant DNA technology, synthetic chemistry techniques were used to manufacture peginesatide, a synthetic peptide that bore no resemblance to previous erythropoiesis-stimulating agents (ESAs), and yet was capable of stimulating erythropoiesis. Compared with other ESAs, peginesatide was deemed to have advantages related to immunogenicity, administration schedule, and cost...
October 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27540636/utilizing-national-and-international-registries-to-enhance-pre-market-medical-device-regulatory-evaluation
#12
Lilly Q Yue, Gregory Campbell, Nelson Lu, Yunling Xu, Bram Zuckerman
Regulatory decisions are made based on the assessment of risk and benefit of medical devices at the time of pre-market approval and subsequently, when post-market risk-benefit balance needs reevaluation. Such assessments depend on scientific evidence obtained from pre-market studies, post-approval studies, post-market surveillance studies, patient perspective information, as well as other real world data such as national and international registries. Such registries provide real world evidence and are playing a more and more important role in enhancing the safety and effectiveness evaluation of medical devices...
August 19, 2016: Journal of Biopharmaceutical Statistics
https://www.readbyqxmd.com/read/27401360/smartpill%C3%A2-as-an-objective-parameter-for-determination-of-severity-and-duration-of-postoperative-ileus-study-protocol-of-a-prospective-two-arm-open-label-trial-the-pidusa-study
#13
Tim O Vilz, Dimitrios Pantelis, Philipp Lingohr, Rolf Fimmers, Anke Esmann, Thomas Randau, Jörg C Kalff, Martin Coenen, Sven Wehner
INTRODUCTION: Postoperative ileus (POI) is a frequent complication after abdominal surgery (AS). Until today, neither a prophylaxis nor an evidence-based therapy exists. This originates from the absence of objective parameters evaluating the severity and duration of POI resulting in clinical trials of modest quality. The SmartPill(®), a capsule which frequently measures pH value, temperature and intraluminal pressure after swallowing, offers an elegant option for analysing gastrointestinal (GI) transit times and smooth muscle activity in vivo...
July 8, 2016: BMJ Open
https://www.readbyqxmd.com/read/27297974/regulatory-approaches-to-non-clinical-reproductive-toxicity-testing-of-anti-cancer-drugs
#14
Georg Schmitt, Paul Barrow
This paper reviews the non-clinical reproductive toxicity testing of 15 drugs currently approved in the USA or Europe for the treatment of cancer. The list includes cytotoxic anti-tumour agents, small molecule inhibitors of pathways involved in neoplastic proliferation, monoclonal antibodies that target specific antigens expressed by neoplastic cells and supportive therapies used to counter the effects of chemotherapy. Most, but not all, drugs were tested for developmental or reproductive toxicity in animals prior to marketing and most were found to be embryotoxic or teratogenic...
June 13, 2016: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/27285978/medicare-and-amyloid-pet-imaging-the-battle-over-evidence
#15
Karen J Maschke, Michael K Gusmano
We examine a recent dispute regarding the Centers for Medicare and Medicaid Services's (CMS) refusal to unconditionally pay for amyloid PET imaging for Medicare beneficiaries being assessed for Alzheimer's disease. CMS will only pay for amyloid PET imaging when patients are enrolled in clinical trials that meet certain criteria. The dispute reflects CMS's willingness in certain circumstances to require effectiveness evidence that differs from the Food and Drug Administration's standard for pre-market approval of a medical intervention and reveals how stakeholders with differing perspectives about evidentiary standards have played a role in attempting to shape the Medicare program's coverage policies...
June 10, 2016: Journal of Aging & Social Policy
https://www.readbyqxmd.com/read/27259384/impact-of-rosiglitazone-safety-alerts-on-oral-antidiabetic-sales-trends-a-countrywide-study-in-portugal
#16
Maria T Herdeiro, Sara Soares, Tânia Silva, Fátima Roque, Adolfo Figueiras
Pharmacovigilance systems are important to monitor the safety of on-market drugs after approval. The aim of this study was to assess the impact of rosiglitazone safety alerts on trends in the sale of rosiglitazone and other oral antidiabetic drugs. An ecological study was conducted, using temporally aggregated data and linking safety alerts to countrywide sales of all oral antidiabetic drugs in Portugal from January 2002 to December 2012. Sales figures for oral antidiabetic drugs marketed in Portugal were supplied by IMS Health Portugal with a breakdown by active substance and fixed combinations...
October 2016: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/27164115/unexploited-antineoplastic-effects-of-commercially-available-anti-diabetic-drugs
#17
REVIEW
Panagiota Papanagnou, Theodora Stivarou, Maria Tsironi
The development of efficacious antitumor compounds with minimal toxicity is a hot research topic. Numerous cancer cell targeted agents are evaluated daily in laboratories for their antitumorigenicity at the pre-clinical level, but the process of their introduction into the market is costly and time-consuming. More importantly, even if these new antitumor agents manage to gain approval, clinicians have no former experience with them. Accruing evidence supports the idea that several medications already used to treat pathologies other than cancer display pleiotropic effects, exhibiting multi-level anti-cancer activity and chemosensitizing properties...
May 6, 2016: Pharmaceuticals
https://www.readbyqxmd.com/read/27133890/tenofovir-alafenamide-taf-as-the-successor-of-tenofovir-disoproxil-fumarate-tdf
#18
Erik De Clercq
Tenofovir alafenamide (TAF) can be considered a new prodrug of tenofovir (TFV), as successor of tenofovir disoproxil fumarate (TDF). It is in vivo as potent against human immunodeficiency virus (HIV) at a 30-fold lower dose (10mg) than TDF (300mg). TAF has been approved in November 2015 (in the US and EU), as a single-tablet regimen (STR) containing 150mg elvitegravir (E), 150mg cobicistat (C), 200mg emtricitabine [(-)FTC] (F) and 10mg TAF, marketed as Genvoya®, on 01 March 2016 in the US as an STR containing 25mg rilpivirine (R), 200mg F and 25mg TAF, marketed as Odefsey®, and on 4 April 2016 in the US, as an STR containing 200mg F and 25mg TAF, marketed as Descovy®, for the treatment of HIV infections...
November 1, 2016: Biochemical Pharmacology
https://www.readbyqxmd.com/read/27123918/analysis-of-adherence-persistence-and-surgery-among-endometriosis-patients-treated-with-leuprolide-acetate-plus-norethindrone-acetate-add-back-therapy
#19
Ahmed M Soliman, Machaon Bonafede, Amanda M Farr, Jane Castelli-Haley, Craig Winkel
BACKGROUND: Endometriosis affects over 10 million women in the United States. Depot leuprolide acetate (LA), a gonadotropin-releasing hormone agonist, has been used extensively for the treatment of women with endometriosis but is associated with hypoestrogenic symptoms and bone mineral density loss. The concomitant use of add-back therapies, specifically norethindrone acetate (NETA), can alleviate these adverse effects. OBJECTIVE: To compare adherence to and persistence with LA treatment and time to endometriosis-related surgery among women treated with NETA and women treated with LA plus other add-back therapies or LA only...
May 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27074333/aripiprazole-lauroxil-long-acting-injectable-the-latest-addition-to-second-generation-long-acting-agents
#20
Arpit Aggarwal, Ganesh Gopalakrishna, John Lauriello
Antipsychotics have long been the mainstay for the treatment of schizophrenia and other psychotic disorders. Long-acting injectables (LAI) of antipsychotics-provided once every two weeks to once every three months-promise to reduce the incidence of nonadherence. ARISTADA(™) (aripiprazole lauroxil; ALLAI) extended-release injectable suspension was approved by the U.S. Food and Drug Administration in October 2015 for the treatment of schizophrenia, and is the newest entrant in the LAI market. ALLAI is available as a single-use, pre-filled syringe, can be started in three different dosages, and also has the option of every six-week dosing...
2016: Clinical Schizophrenia & related Psychoses
keyword
keyword
57642
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"